Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: Diagnostic and therapeutic implications

Michael Sever, Timothy D. Jones, Lawrence M. Roth, Fadi W Abdul Karim, Wenxin - Zheng, Helen Michael, Eyas M. Hattab, Robert E. Emerson, Lee Ann Baldridge, Liang Cheng

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The proto-oncogene c-kit encodes a tyrosine kinase receptor, c-kit (CD117), which has been implicated in the development of a number of human malignancies. While the preferential expression of this protein has been well documented in testicular seminomas, there is little data concerning its expression in dysgerminomas of the ovary. We examined the expression of c-kit in 30 cases of ovarian dysgerminomas using immunohistohemical staining with a polyclonal anti-CD117 antibody. Staining was graded in a semiquantitative manner as follows: negative (no staining), 1+ (1-10% staining), 2+ (10-29% staining), 3+ (30-50% staining), or 4+ (>50% staining). Of the 30 cases examined, 26 (87%) demonstrated immunoreactivity for CD117. In total, 10 (33%) demonstrated 4+ staining; 9 (30%) demonstrated 3+ staining; 3 (10%) demonstrated 2+ staining; 4 (13%) demonstrated 1+ staining; and 4 (13%) demonstrated no staining. In conclusion, CD117 immunoreactivity was detected in 87% of ovarian dysgerminomas, a finding that correlates with previously reported frequencies of CD117 expression in seminomas (78-100%). Thus, antibodies to c-kit may be a useful diagnostic marker for ovarian dysgerminoma. Although the prognosis of patients with dysgerminoma is generally good, this receptor could potentially serve as a target for site-specific immunotherapy as an alternative and/or complement to conventional treatment options.

Original languageEnglish (US)
Pages (from-to)1411-1416
Number of pages6
JournalModern Pathology
Volume18
Issue number11
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Dysgerminoma
Proto-Oncogene Proteins c-kit
Ovary
Staining and Labeling
Therapeutics
Seminoma
Negative Staining
Proto-Oncogenes
Receptor Protein-Tyrosine Kinases
Immunotherapy
Anti-Idiotypic Antibodies

Keywords

  • c-kit (CD117)
  • Differential diagnosis
  • Dysgerminoma
  • Germ cell tumors
  • OCT4
  • Ovary

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary : Diagnostic and therapeutic implications. / Sever, Michael; Jones, Timothy D.; Roth, Lawrence M.; Karim, Fadi W Abdul; Zheng, Wenxin -; Michael, Helen; Hattab, Eyas M.; Emerson, Robert E.; Baldridge, Lee Ann; Cheng, Liang.

In: Modern Pathology, Vol. 18, No. 11, 11.2005, p. 1411-1416.

Research output: Contribution to journalArticle

Sever, M, Jones, TD, Roth, LM, Karim, FWA, Zheng, W, Michael, H, Hattab, EM, Emerson, RE, Baldridge, LA & Cheng, L 2005, 'Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: Diagnostic and therapeutic implications', Modern Pathology, vol. 18, no. 11, pp. 1411-1416. https://doi.org/10.1038/modpathol.3800463
Sever, Michael ; Jones, Timothy D. ; Roth, Lawrence M. ; Karim, Fadi W Abdul ; Zheng, Wenxin - ; Michael, Helen ; Hattab, Eyas M. ; Emerson, Robert E. ; Baldridge, Lee Ann ; Cheng, Liang. / Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary : Diagnostic and therapeutic implications. In: Modern Pathology. 2005 ; Vol. 18, No. 11. pp. 1411-1416.
@article{ccdbc7ce01334180bb493b709b41de9e,
title = "Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: Diagnostic and therapeutic implications",
abstract = "The proto-oncogene c-kit encodes a tyrosine kinase receptor, c-kit (CD117), which has been implicated in the development of a number of human malignancies. While the preferential expression of this protein has been well documented in testicular seminomas, there is little data concerning its expression in dysgerminomas of the ovary. We examined the expression of c-kit in 30 cases of ovarian dysgerminomas using immunohistohemical staining with a polyclonal anti-CD117 antibody. Staining was graded in a semiquantitative manner as follows: negative (no staining), 1+ (1-10{\%} staining), 2+ (10-29{\%} staining), 3+ (30-50{\%} staining), or 4+ (>50{\%} staining). Of the 30 cases examined, 26 (87{\%}) demonstrated immunoreactivity for CD117. In total, 10 (33{\%}) demonstrated 4+ staining; 9 (30{\%}) demonstrated 3+ staining; 3 (10{\%}) demonstrated 2+ staining; 4 (13{\%}) demonstrated 1+ staining; and 4 (13{\%}) demonstrated no staining. In conclusion, CD117 immunoreactivity was detected in 87{\%} of ovarian dysgerminomas, a finding that correlates with previously reported frequencies of CD117 expression in seminomas (78-100{\%}). Thus, antibodies to c-kit may be a useful diagnostic marker for ovarian dysgerminoma. Although the prognosis of patients with dysgerminoma is generally good, this receptor could potentially serve as a target for site-specific immunotherapy as an alternative and/or complement to conventional treatment options.",
keywords = "c-kit (CD117), Differential diagnosis, Dysgerminoma, Germ cell tumors, OCT4, Ovary",
author = "Michael Sever and Jones, {Timothy D.} and Roth, {Lawrence M.} and Karim, {Fadi W Abdul} and Zheng, {Wenxin -} and Helen Michael and Hattab, {Eyas M.} and Emerson, {Robert E.} and Baldridge, {Lee Ann} and Liang Cheng",
year = "2005",
month = "11",
doi = "10.1038/modpathol.3800463",
language = "English (US)",
volume = "18",
pages = "1411--1416",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary

T2 - Diagnostic and therapeutic implications

AU - Sever, Michael

AU - Jones, Timothy D.

AU - Roth, Lawrence M.

AU - Karim, Fadi W Abdul

AU - Zheng, Wenxin -

AU - Michael, Helen

AU - Hattab, Eyas M.

AU - Emerson, Robert E.

AU - Baldridge, Lee Ann

AU - Cheng, Liang

PY - 2005/11

Y1 - 2005/11

N2 - The proto-oncogene c-kit encodes a tyrosine kinase receptor, c-kit (CD117), which has been implicated in the development of a number of human malignancies. While the preferential expression of this protein has been well documented in testicular seminomas, there is little data concerning its expression in dysgerminomas of the ovary. We examined the expression of c-kit in 30 cases of ovarian dysgerminomas using immunohistohemical staining with a polyclonal anti-CD117 antibody. Staining was graded in a semiquantitative manner as follows: negative (no staining), 1+ (1-10% staining), 2+ (10-29% staining), 3+ (30-50% staining), or 4+ (>50% staining). Of the 30 cases examined, 26 (87%) demonstrated immunoreactivity for CD117. In total, 10 (33%) demonstrated 4+ staining; 9 (30%) demonstrated 3+ staining; 3 (10%) demonstrated 2+ staining; 4 (13%) demonstrated 1+ staining; and 4 (13%) demonstrated no staining. In conclusion, CD117 immunoreactivity was detected in 87% of ovarian dysgerminomas, a finding that correlates with previously reported frequencies of CD117 expression in seminomas (78-100%). Thus, antibodies to c-kit may be a useful diagnostic marker for ovarian dysgerminoma. Although the prognosis of patients with dysgerminoma is generally good, this receptor could potentially serve as a target for site-specific immunotherapy as an alternative and/or complement to conventional treatment options.

AB - The proto-oncogene c-kit encodes a tyrosine kinase receptor, c-kit (CD117), which has been implicated in the development of a number of human malignancies. While the preferential expression of this protein has been well documented in testicular seminomas, there is little data concerning its expression in dysgerminomas of the ovary. We examined the expression of c-kit in 30 cases of ovarian dysgerminomas using immunohistohemical staining with a polyclonal anti-CD117 antibody. Staining was graded in a semiquantitative manner as follows: negative (no staining), 1+ (1-10% staining), 2+ (10-29% staining), 3+ (30-50% staining), or 4+ (>50% staining). Of the 30 cases examined, 26 (87%) demonstrated immunoreactivity for CD117. In total, 10 (33%) demonstrated 4+ staining; 9 (30%) demonstrated 3+ staining; 3 (10%) demonstrated 2+ staining; 4 (13%) demonstrated 1+ staining; and 4 (13%) demonstrated no staining. In conclusion, CD117 immunoreactivity was detected in 87% of ovarian dysgerminomas, a finding that correlates with previously reported frequencies of CD117 expression in seminomas (78-100%). Thus, antibodies to c-kit may be a useful diagnostic marker for ovarian dysgerminoma. Although the prognosis of patients with dysgerminoma is generally good, this receptor could potentially serve as a target for site-specific immunotherapy as an alternative and/or complement to conventional treatment options.

KW - c-kit (CD117)

KW - Differential diagnosis

KW - Dysgerminoma

KW - Germ cell tumors

KW - OCT4

KW - Ovary

UR - http://www.scopus.com/inward/record.url?scp=27144487758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144487758&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800463

DO - 10.1038/modpathol.3800463

M3 - Article

C2 - 16056250

AN - SCOPUS:27144487758

VL - 18

SP - 1411

EP - 1416

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 11

ER -